e-learning
resources
Amsterdam 2015
Tuesday, 29.09.2015
Treatment of IPF
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib
Vincent Cottin (Lyon, France), Vincent Cottin, Huiping Li, Fabrizio Luppi, Florence Le Maulf, Rozsa Schlenker-Herceg, Susanne Stowasser, Roland M. Du Bois
Source:
International Congress 2015 – Treatment of IPF
Session:
Treatment of IPF
Session type:
Oral Presentation
Number:
4498
Disease area:
Interstitial lung diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Vincent Cottin (Lyon, France), Vincent Cottin, Huiping Li, Fabrizio Luppi, Florence Le Maulf, Rozsa Schlenker-Herceg, Susanne Stowasser, Roland M. Du Bois. Effect of baseline corticosteroid medication on reduction in FVC decline with nintedanib. Eur Respir J 2015; 46: Suppl. 59, 4498
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion: ANCA associated vasculitis and lung disease
Panel discussion on genetics in pulmonary fibrosis
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Related content which might interest you:
Effect of anti-acid medication on reduction in FVC decline with nintedanib
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Effect of baseline FVC on lung function decline with nintedanib in patients with IPF
Source: International Congress 2015 – Treatment of IPF
Year: 2015
Effect of baseline statin use on benefit of nintedanib
Source: International Congress 2016 – IPF treatment II
Year: 2016
Effect of baseline composite physiologic index on benefit of nintedanib in IPF
Source: International Congress 2016 – IPF treatment I
Year: 2016
Real World experiences: Pirfenidone is well tolerated and reduces decline in FVC and TLCO at 9 months in IPF
Source: Annual Congress 2013 –Diffuse pulmonary fibrosis
Year: 2013
Relationship between nintedanib exposure and adverse events in patients with idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF treatment II
Year: 2016
Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON
Source: International Congress 2016 – IPF treatment II
Year: 2016
Long-term safety of combination therapy with nintedanib and pirfenidone in Japanese patients with IPF
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Differences in FVC decline by extent of emphysema in patients with combined pulmonary fibrosis and emphysema (CPFE) syndrome
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
Efficacy and safety of nintedanib in advanced idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Intravenous pulse doses of high-dose corticosteroid and cyclophosphamide in acute exacerbation of idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Effect of baseline FVC on decline in lung function with nintedanib: Results from the INPULSIS™ trials
Source: International Congress 2014 – Clinical trials in IPF
Year: 2014
Effect of continued pirfenidone treatment following a ≥ 15% decline in 6-minute walk distance (6MWD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis from 3 pivotal studies
Source: International Congress 2016 – New and old therapies for chronic lung diseases
Year: 2016
Clinical experience with pirfenidone for the treatment of idiopathic pulmonary fibrosis
Source: Annual Congress 2013 –Diffuse parenchymal lung disease III
Year: 2013
Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
Source: International Congress 2016 – IPF treatment I
Year: 2016
Efficacy of pirfenidone in idiopathic pulmonary fibrosis: A single center experience
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Clinical experience with nintedanib for the treatment of IPF in 80 cases
Source: International Congress 2016 – IPF: from pathogenesis to treatment II
Year: 2016
Severe pulmonary hypertension in patients with emphysema but preserved FEV1: Prognosis and response to treatment
Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension I
Year: 2013
Negative outcome of prednisone in possible idiopathic pulmonary fibrosis
Source: International Congress 2016 – IPF clinical
Year: 2016
No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib
Source: International Congress 2016 – IPF treatment II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept